Hummingbird's HER3-targeted ADC entices Endeavor to sign $430M licensing deal
License out/inADC
Preview
Source: FierceBiotech
Hummingbird has designed HMBD-501 to have “a wider therapeutic index” than other HER3 ADCs in development.
The buzz around HER3-targeting antibody-drug conjugates (ADCs) continues to grow. Only a week after BioNtech got in on the action, Endeavor BioMedicines has secured the rights to Hummingbird Bioscience’s preclinical contender.
The companies aren’t breaking down the financial details of the deal, but we do know that Hummingbird will be eligible to receive upfront and milestone payments from Endeavor totaling up to $430 million, plus a slice of the royalties. In return, it’s handing over the exclusive worldwide license of HMBD-501, a next-generation HER3-targeted ADC with an exatecan payload.
While AstraZeneca and Daiichi Sankyo have enjoyed success with their HER2-directed ADC Enhertu, companies have already turned to HER3 as another target of interest. Daiichi itself is working on a candidate called patritumab deruxtecan, while BioNTech paid $70 million upfront last week for MediLink Therapeutics’s own entrant in the space.
“This exclusive license with Hummingbird Bio provides Endeavor with a potential best-in-class HER3-ADC, with the opportunity to treat a large number of patients in multiple tumor types,” Hood added in the Oct. 19 release. “This next-generation ADC has the potential to address significant unmet clinical needs in areas left behind by HER2 agents.”
Hummingbird has designed HMBD-501 with the aim of being a “best in class” HER3 ADC that has “a wider therapeutic index” than other options in development, the biotech’s CEO Piers Ingram, Ph.D., explained in the release. “We are pleased to license HMBD-501 to the experienced Endeavor team to bring the molecule into the clinic and a step closer to benefiting patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.